Topical therapy in anosmia: Relevance of steroid-responsiveness

Laryngoscope

Volumn 118, Issue 9, 2008, Pages 1681-1686

  Stenner, M ^a   Vent, J ^a   Huttenbrink K B ^a   Hummel, T ^b   Damm, M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antibiotics; Corticosteroids; Olfactory dysfunction; Steroid responsiveness; Topical therapy

Indexed keywords

BETAMETHASONE; BUDESONIDE; CELESTAMINE; NEOMYCIN; ANTIINFECTIVE AGENT; GLUCOCORTICOID;

ADULT; AGED; ANOSMIA; ARTICLE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHINOSINUSITIS; SMELLING; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; ODOR; PATHOPHYSIOLOGY; PHYSIOLOGY; SMELLING DISORDER;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NEOMYCIN; OLFACTION DISORDERS; RETROSPECTIVE STUDIES; SMELL; TREATMENT OUTCOME;

EID: 51649118644     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31817c1368     Document Type: Article

References (18)

1. Bramerson A., Johansson L., Ek L., Nordin S., Bende M. Prevalence of olfactory dysfunction: the skövde populationbased study. Laryngoscope 2004;114:733-737.
2. Jafek BW, Murrow B., Michaels R., Restrepo D., Linschoten M. Biopsies of human olfactory epithelium. Chem Senses 2002;27:623-628.
3. Hummel T., Heilmann S., Hüttenbrink KB. Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. Laryngoscope 2002;112: 2076-2080.
4. Stevens MH. Steroid-dependent anosmia. Laryngoscope 2001;111:200-203.
5. Fong KJ, Kern RC, Foster JD, Zhao JC, Pitovski DZ. Olfactory secretion and sodium, potassium-adenosine triphosphatase: regulation by corticosteroids. Laryngoscope 1999; 109:383-388.
6. Kern RC, Conley DB, Haines GK, Robinson AM. Treatment of olfactory dysfunction. II. Studies with minocycline. Laryngoscope 2004;114:2200-2204.
7. el Naggar M., Kale S., Aldren C., Martin F. Effect of Beconase nasal spray on olfactory function in post-nasal polypectomy patients: a prospective controlled trial. J Laryngol Otol 1995;109:941-944.
8. Kratskin IL, Kimura Y., Hastings L., Doty RL. Chronic dexamethasone treatment potentiates insult to olfactory receptor cells produced by 3-methylindole. Brain Res 1999;847: 240-246.
9. Blomqvist EH, Lundblad L., Bergstedt H., Stjarne P. Placebocontrolled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of patients with hyposmia/anosmia. Acta Otolaryngol 2003;123:862-868.
10. Fein BJ, Kamin PB, Fein NA. The loss of sense of smell in nasal allergy. Ann Allergy 1966;24:278-279.
11. Hummel T., Kobal G., Gudziol H., Mackay-Sim A. Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 2007;264:237-243.
12. Damm M., Temmel A., Welge-Lussen A., et al. [Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland]. HNO 2004;52:112-120.
13. Ikeda K., Sakurada T., Suzaki Y., Takasaka T. Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease. Rhinology 1995;33:162-165.
14. Stuck BA, Blum A., Hagner AE, Hummel T., Klimek L., Hörmann K. Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis. Allergy 2003;58:1195.
15. Robinson AM, Kern RC, Foster JD, Fong KJ, Pitovski DZ. Expression of glucocorticoid receptor mRNA and protein in the olfactory mucosa: physiologic and pathophysiologic implications. Laryngoscope 1998;108:1238-1242.
16. Saunders MW, Wheatley AH, George SJ, Lai T., Birchall MA. Do corticosteroids induce apoptosis in nasal polyp inflammatory cells? In vivo and in vitro studies. Laryngoscope 1999;109:785-790.
17. Garcia-Trapero J., Carceller F., Dujovny M., Cuevas P. Perivascular delivery of neomycin inhibits the activation of NF-kappaB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury. Neurol Res 2004;26:816-824.
18. Whatley WS, Chandra RK, MacDonald CB. Systemic absorption of gentamicin nasal irrigations. Am J Rhinol 2006;20: 251-254.